Vaccine based prevention
of Diabetes
Diabetology is currently researching & setting
up pre-clinial studies on different methods
of down-regulating the auto-immune components
of the development of diabetes using its Mozaic
and Vaxcine technologies.
GAD Tolerising Vaccine
A GAD tolerising vaccine is
being developed by Diabetology that employs
their Vaxcine technology.
| Target: |
Prevention of LADA insulin
dependence in Type 2 Diabetes |
| Stage: |
Early Preclinical, IP ownership of antigens
to be clarified |
The
vehicle to be employed for delivery
of GAD via the mucosal route is one
that has already demonstrated efficacy
in enhancing immune responses to bacterial
toxins, and has been employed successfully,
in conjunction with GAD, to reduce the
onset of diabetes in a NOD mouse model
(see elsewhere for description of preliminary
experiments). |
 |
The technology for production
of the vaccine is protected by a patent pending
assigned to Proxima Concepts Ltd. and its
associates (PCT publication number W096/14871).
In brief, the vaccine vehicle consists of
oil droplets inside which protein antigens
are encapsulated stably as a result of being
wrapped in a sheath of amphiphile (New RRC
& Kirby CJ in Advanced Drug Delivery Reviews
25 pp59-69 (1997) “Solubilisation of
hydrophilic drugs in oily formulations”).
 |
The use
of a hydrophobic oil vehicle encourages
uptake of the encapsulated antigens
by M cells of the Peyers patches. New
proprietary technology developed by
Proxima will enable modification of
the vaccine manufacture methodology
to be implemented which will improve
the properties of the delivery vehicle,
increasing markedly its stability and
its control over the quantity of antigen
delivered to the Peyers patches. Using
these improvements, it is expected that
the window of antigen dose administered
displaying efficacy can be broadened,
so that a linear dose-response relationship
can be obtained over a wide dose range,
rather than the biphasic response currently
observed.
|
|
